//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы


Abdollah F. et al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol. 2015;67:212. https://www.ncbi.nlm.nih.gov/pubmed/24882672.

Messing E.M. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472. https://www.ncbi.nlm.nih.gov/pubmed/16750497.

Kuban D.A. et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011;79:1310. https://www.ncbi.nlm.nih.gov/pubmed/20493642.

Matzinger O. et al. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer. 2009;45:2825. https://www.ncbi.nlm.nih.gov/pubmed/19682889.

Jones C.U. et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107. https://www.ncbi.nlm.nih.gov/pubmed/21751904.

D’Amico A.V. et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289. https://www.ncbi.nlm.nih.gov/pubmed/18212313.

Ash D. et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000;57:315. https://www.ncbi.nlm.nih.gov/pubmed/11104892.

Ramsay C.R. et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2015;19:1. https://www.ncbi.nlm.nih.gov/pubmed/26140518.

Pagliarulo V. et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012;61:11. https://www.ncbi.nlm.nih.gov/pubmed/21871711.

Seidenfeld J. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132:566. https://www.ncbi.nlm.nih.gov/pubmed/10744594.

//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы


Crawford E.D. et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011;186:889. https://www.ncbi.nlm.nih.gov/pubmed/21788033.

Smith M.R. et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004;22:2546. https://www.ncbi.nlm.nih.gov/pubmed/15226323.

Montgomery R.B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447. https://www.ncbi.nlm.nih.gov/pubmed/18519708.

James N.D. et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028. https://www.ncbi.nlm.nih.gov/pubmed/25301760.

Eisenberger M.A. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036. https://www.ncbi.nlm.nih.gov/pubmed/9761805.

Vale C.L. et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2015. https://www.ncbi.nlm.nih.gov/pubmed/26718929.

Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163:1632. https://www.ncbi.nlm.nih.gov/pubmed/10799151.

Ustinova T.V., Nyushko K.M., Bolotina L.V., Kharchenko N.V., Paychadze A.A., Taraki I.A., Alekseev B. Ya., Krasheninnikov A.A., Kaprin A.D. Neoadjuvant And Adjuvant Chemohormonal Therapy In Patients With High-Risk And Very High-Risk Prostate Cancer: Our Experience. doi: 10.17650/1726-9776-2018-14-3-58-67.

Roach M. 3rd et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: